HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mayer, J. E. Articles by Nicoloff, D. M. Search for Related Content PubMed PubMed Citation Articles by Mayer, J. E., Jr. Articles by Nicoloff, D. M.

Ann Thorac Surg 1981;31:204-210
© 1981 The Society of Thoracic Surgeons

---

Articles

Influence of Aspirin and Dipyridamole on Patency of Coronary Artery Bypass Grafts

Departments of Surgery and Radiology, University of Minnesota, Minneapolis, MN

^* Address reprint requests to Dr. Nicoloff, 2545 Chicago Ave S, Suite G10, Minneapolis, MN 55404

A prospective randomized trial was performed to determine if the administration of inhibitors of platelet function would improve the patency of coronary artery bypass grafts. Patients were operated on for intractable angina with angiographically demonstrable lesions. The left internal mammary artery (IMA) was used for bypass of lesions of the left anterior descending coronary artery (LAD). Saphenous vein grafts were used for the LAD if the IMA was inadequate and for all other vessels. Treated patients received 1,300 mg of aspirin and 100 mg of dipyridamole (Persantine) orally each day. Control patients received neither drug. Patients returned 3 to 6 months after operation for repeat angiography. Results were analyzed by chi-square.

One hundred seventy-four patients entered the study from June, 1973, through December, 1975, and 113 were analyzed. In the control group, 66 patients had 27 IMA-LAD grafts and 93 saphenous vein grafts. In the treatment group, 47 patients underwent 18 IMA-LAD grafts and 75 saphenous vein grafts. Ninety-eight of the 120 grafts (82%) were patent in the control group, and 87 of 93 grafts (94%) were patent in the treatment group (x² = 6.34, p < 0.02). Of the 45 IMA-LAD grafts in both groups, only 1 was occluded, a patency of 98%. In the control group, 72 of 93 saphenous vein grafts (77%) were patent. In the treatment group, 69 of 75 (92%) were patent (x² = 6.54, p < 0.02). The results of the study show a 15% difference between the two groups in the early patency of saphenous vein grafts. We continue to use aspirin and dipyridamole to improve the patency of saphenous vein bypass grafts.

This article has been cited by other articles:

				R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 776S - 814S. [Abstract] [Full Text] [PDF]

				P. D. Stein, H. J. Schunemann, J. E. Dalen, and D. Gutterman Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 600S - 608S. [Abstract] [Full Text] [PDF]

				E. Lim, Z. Ali, A. Ali, T. Routledge, L. Edmonds, D. G Altman, and S. Large Indirect comparison meta-analysis of aspirin therapy after coronary surgery BMJ, December 6, 2003; 327(7427): 1309. [Abstract] [Full Text] [PDF]

				P. D. Stein, J. E. Dalen, S. Goldman, and P. Theroux Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts Chest, January 1, 2001; 119(2009): 278S - 282S. [Full Text] [PDF]

				Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]

				J. B. Wong, F. A. Sonnenberg, D. N. Salem, and S. G. Pauker Myocardial Revascularization for Chronic Stable Angina: Analysis of the Role of Percutaneous Transluminal Coronary Angioplasty Based on Data Available in 1989 Ann Intern Med, December 1, 1990; 113(11): 852 - 871. [Abstract] [PDF]

				G. P. Clagett Antithrombotic Drugs and Vascular Surgery Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1990; 3(2): 79 - 102. [PDF]

				W. G. Henderson, S. Goldman, J. G. Copeland, T. E. Moritz, and L. A. Harker Antiplatelet or Anticoagulant Therapy after Coronary Artery Bypass Surgery: A Meta-Analysis of Clinical Trials Ann Intern Med, November 1, 1989; 111(9): 743 - 750. [Abstract] [PDF]

				G. L. Hicks Jr., L. A. Jensen, L. H. Norsen, J. R. Quinn, S. S. Stewart, and J. A. DeWeese Platelet Inhibitors and Hydroxyethyl Starch: Safe and Cost-Effective Interventions in Coronary Artery Surgery Ann. Thorac. Surg., May 1, 1985; 39(5): 422 - 425. [Abstract] [PDF]

				M. Chevigne, J.- L. David, P. Rigo, and R. Limet Effect of Ticlopidine on Saphenous Vein Bypass Patency Rates: A Double-blind Study Ann. Thorac. Surg., May 1, 1984; 37(5): 371 - 378. [Abstract] [PDF]